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Cardiovascular risk factors in chronic kidney disease
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Cardiovascular disease is the primary cause of morbid-
ity and premature mortality in chronic kidney disease.
While it is well established that patients with kidney fail-
ure (chronic kidney disease stage 5) are at high risk of
cardiovascular disease morbidity and mortality [1], pa-
tients with earlier stages of chronic kidney disease also
experience a high rate of fatal and nonfatal cardiovascu-
lar events [2]. Recent guidelines and position statements
have therefore defined chronic kidney disease as a car-
diovascular risk equivalent, and patients in all stages of
chronic kidney disease are considered in the “highest risk
group” for development of cardiovascular disease [3].
We propose that patients with chronic kidney dis-
ease are at increased risk for cardiovascular disease for
several reasons (Fig. 1): (1) chronic kidney disease is asso-
ciated with increased prevalence of traditional and non-
traditional cardiovascular disease risk factors; (2) chronic
kidney disease is an independent risk factor for cardiovas-
cular disease; (3) many cardiovascular disease risk factors
are also risk factors for progression of chronic kidney dis-
ease; and (4) the presence of cardiovascular disease may
be a risk factor for chronic kidney disease. The interrela-
tionship between cardiovascular and chronic kidney dis-
ease, with each contributing to the pathogenesis of the
other, leads to a cycle of cardiovascular and kidney dis-
ease progression.
In the current review we focus on chronic kidney dis-
ease stages 1 to 4 and (1) present evidence suggesting
that markers of chronic kidney disease, including reduced
glomerular filtration rate (GFR) and microalbuminuria,
are independent risk factors for cardiovascular disease,
(2) describe the spectrum of cardiovascular disease in
chronic kidney disease, and (3) discuss the role of tradi-
tional and nontraditional risk factors in the development
of the different forms of cardiovascular disease. We do
not describe management strategies as this is discussed
in an accompanying review.
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CHRONIC KIDNEY DISEASE AS AN
INDEPENDENT RISK FACTOR FOR
CARDIOVASCULAR DISEASE
Reduced GFR as risk factor for cardiovascular disease
An abundance of recent data has demonstrated an
association between reduced kidney function and cardio-
vascular disease morbidity and mortality that persists af-
ter adjustment for traditional cardiovascular disease risk
factors [2, 4]. Possible explanations for this association
include that reduced GFR (1) is associated with an in-
creased level of non-traditional risk factors that are fre-
quently not adjusted for in analyses, (2) may be a marker
of the severity of diagnosed vascular disease or of undiag-
nosed vascular disease, (3) may be a measure of residual
confounding from traditional risk factors, for example,
the severity of hypertension, and (4) patients with re-
duced GFR may not receive the benefits of optimal thera-
pies such as aspirin, beta blockers, angiotensin-converting
enzyme (ACE) inhibitors.
Microalbuminuria as a risk factor for
cardiovascular disease
Prospective studies have established that albumin ex-
cretion, at levels well below the current cutoffs used to
define microalbuminuria, is an independent predictor of
cardiovascular disease outcomes [5]. Potential reasons for
these findings include the following: (1) microalbumin-
uria may be a marker of generalized endothelial dysfunc-
tion and vascular permeability, (2) microalbuminuria may
be associated with other traditional and nontraditional
cardiovascular disease risk factors, and (3) microalbumin-
uria may be a precursor for the development of early or
incipient kidney disease. In support of the last hypoth-
esis, studies have demonstrated that microalbuminuria
is associated with an increased risk for development of
albuminuria, an accepted marker of kidney disease [6].
SPECTRUM OF CARDIOVASCULAR DISEASE IN
CHRONIC KIDNEY DISEASE
Manifestations of cardiovascular disease in chronic
kidney disease can be broadly classified as those affecting
1413
1414 Menon et al: Cardiovascular risk factors in chronic kidney disease
Traditional
cardiovascular
risk factors
Nontraditional
cardiovascular
risk factors
CVD
CKD
Fig. 1. Chronic kidney disease (CKD) is a risk factor for cardiovas-
cular disease (CVD) and cardiovascular disease may be a risk factor
for progression of chronic kidney disease. Traditional cardiovascular
disease risk factors promote the development and progression of both
chronic kidney disease and cardiovascular disease. Declining kidney
function is associated with elevated levels of traditional and nontradi-
tional cardiovascular disease risk factors. It remains unknown whether
nontraditional cardiovascular disease risk factors (dotted arrow) are
important risk factors for progression of kidney disease. Reproduced
with permission from [7].
the myocardium and those affecting the blood vessels al-
though these pathophysiologic processes are not mutu-
ally exclusive and are in fact closely interrelated (Fig.
2). As described below, clinical manifestations of my-
ocardial and vascular remodeling include left ventricu-
lar hypertrophy (LVH), increased pulse pressure, and
ischemic heart disease, all of which are independent
risk factors for mortality in patients with kidney failure
[8–10].
Myocardium
The pressure and volume overload that are inherent to
the abnormalities of homeostasis seen in chronic kidney
disease lead to structural alterations of the myocardium
[11]. These structural changes include ventricular re-
modeling that may lead to eccentric or concentric LVH,
systolic and diastolic dysfunction, and resultant clinical
symptoms of heart failure.
Abnormalities of myocardial structure are common in
chronic kidney disease. The prevalence of LVH was 30%
in a cohort of patients with chronic kidney disease stages
3 and 4 [12]. In a large cohort derived from a health
maintenance organization, the prevalence of heart fail-
ure ranged from 5% to 21% among patients with GFR
of 15 to 60 mL/min/1.73 m2 [4]. In a community-based
cohort of patients with heart failure, 55% had creatinine
clearance <59 mL/min [13].
Blood vessels
The hemodynamic and metabolic milieu evident in
chronic kidney disease facilitates arterial remodeling.
The resultant structural abnormalities include changes
in the arterial lumen as well as components of the ves-
sel wall [14]. Manifestations of intimal disease include
atherosclerotic plaque formation and subsequent devel-
opment of coronary artery disease and ischemic heart
disease. Structural changes in the arterial wall such as
increased collagen, calcification and extracellular matrix
result in arteriosclerosis and arterial stiffening.
There is a high prevalence of both atherosclerosis and
arteriosclerosis in chronic kidney disease. A coronary
angiographic investigation of predialysis patients with
chronic kidney disease stage 5 with no history of heart
disease noted that 53% of the cohort had significant coro-
nary artery stenosis defined as >50% stenosis [abstract;
Ohtake T et al, J Am Soc Nephrol 9:0765, 2005]. In the
population-based Atherosclerosis Risk in Communities
(ARIC) Study, the prevalence of symptomatic coronary
heart disease was 11% among persons with chronic kid-
ney disease versus 4% in those without kidney disease [2].
There was a significant association between arterial stiff-
ness, estimated as pulse wave velocity, and kidney func-
tion in a cohort of patients with mean creatinine clearance
of 68.5 mL/min/1.73 m2 [15].
Interrelationships of different forms of
cardiovascular disease
The consequences of arteriosclerosis and loss of arte-
rial compliance include increased afterload that in turn
causes ventricular hypertrophy thus setting up a cycle of
deteriorating myocardial function [13]. In turn, LVH in-
creases myocardial oxygen demand thus further exacer-
bating ischemic heart disease.
RISK FACTORS FOR CARDIOVASCULAR
DISEASE IN CHRONIC KIDNEY DISEASE
Both traditional and nontraditional risk factors have
been implicated in the development of cardiovascular
disease in chronic kidney disease. Traditional risk fac-
tors are those defined in the Framingham Heart Study
and used to predict coronary heart disease outcomes in
the general population [16]. Nontraditional risk factors
are uremia-related factors that increase in prevalence as
kidney function declines and may contribute to the ex-
cess risk of cardiovascular disease seen in chronic kidney
disease [3] (Table 1).
Risk factors for LVH
Systolic blood pressure and anemia appear to be
important determinants of left ventricular remodeling in
patients with kidney disease [17]. In addition, several tra-
ditional and nontraditional cardiovascular disease factors
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Fig. 2. Traditional and nontraditional risk factors associated with chronic kidney disease may promote myocardial and blood vessel remodeling
resulting in different manifestations of cardiovascular disease (CVD), including cardiomyopathy, atherosclerosis, and arteriosclerosis. The latter
subsequently lead to clinical manifestations of cardiovascular disease, including heart failure and ischemic heart disease.
are implicated in the pathogenesis of LVH in chronic kid-
ney disease. In a cohort of incident dialysis patients from
Dialysis Morbidity and Mortality Study (DMMS) Wave 2,
age, hypertension, diabetes, smoking, and serum calcium
and parathyroid hormone (PTH) levels were correlates
of LVH [18].
Limited data exists on determinants of LVH in patients
in the earlier stages of chronic kidney disease. In a nested
analysis of data from the Australian Predialysis (SLIM-
HEART) Study, LVH was a product of both increased
chamber size as well as wall thickness [11]. In a cross-
sectional study of patients with mean creatinine clearance
of 25 mL/min, older age, higher systolic blood pressure,
lower hemoglobin, and decreased level of kidney function
were independent predictors of LVH [19]. Similarly, in
the ARIC Study, among African Americans with chronic
kidney disease stage 3, lower GFR and lower hemoglobin
were associated with LVH [20].
More recent data suggest that additional nontradi-
tional factors may be implicated in the development
of LVH in kidney disease. In a cross-sectional study of
hemodialysis patients, coronary artery calcification score
and pulse pressure were independent correlates of LVH
[21]. Markers of oxidative stress, discussed later, were
also associated with LVH independent of carotid intima
media thickness and number of plaques in a cohort of
chronic hemodialysis patients [22].
Risk factors for atherosclerosis
There are limited data on traditional atherosclerotic
cardiovascular disease factors in chronic kidney disease
stages 1 to 4. Much of the existing information is extrap-
olated from studies in the general population. However,
this extrapolation for the most part seems reasonable, as
there is no a priori reason to assume that these risk rela-
tionships will widely differ in patients in the earlier stages
of chronic kidney disease.
A few studies have confirmed the importance of tradi-
tional cardiovascular disease risk factors, such as diabetes,
higher total cholesterol, lower high-density lipoprotein
(HDL) cholesterol, smoking, and higher systolic blood
pressure, in the development of atherosclerotic cardio-
vascular disease in chronic kidney disease stages 1 to 4
[23, 24].
Recent studies have suggested that the Framingham
risk equation may be inadequate to attribute risk of coro-
nary heart disease in a person with chronic kidney dis-
ease [25, 26], although this remains to be evaluated in
large prospective studies. A potential explanation for the
Framingham equation being inadequate in chronic kid-
ney disease is the presence of nontraditional factors that
are not accounted for by this equation.
There are few prospective studies or randomized con-
trolled trials evaluating nontraditional factors as risk fac-
tors for the development of cardiovascular disease in
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Table 1. Manifestations of cardiovascular disease in chronic kidney disease and associated putative risk factors
Pathology Traditional risk factors Nontraditional risk factors
Cardiomyopathy Older age Albuminuria
Hypertension Reduced glomerular filtration rate
Valvular disease Anemia
Dyslipidemia Inflammation
Smoking Arteriosclerosis
Diabetes Extracellular fluid volume overload
Abnormal calcium/phosphate metabolism
Atherosclerosis Older age Albuminuria
Male gender Reduced glomerular filtration rate
Hypertension Anemia
Diabetes Inflammation
Dyslipidemia Oxidative stress
Smoking Endothelial dysfunction
Physical inactivity Homocysteine
Left ventricular hypertrophy Lipoprotein(a)
Malnutrition
Thrombogenic factors
Sympathetic activity
Insulin resistance/metabolic syndrome
Arteriosclerosis Older age Albuminuria
Male gender Reduced glomerular filtration rate
Smoking Endothelial dysfunction
Hypertension Abnormal calcium/phosphate metabolism
Diabetes Metabolic syndrome
Dyslipidemia
chronic kidney disease. Available evidence for some of
these risk factors is briefly summarized below. We do not
discuss anemia, as this is the topic of an accompanying
review.
Inflammation
Inflammation appears to play an integral part in the
pathogenesis of atherosclerosis. The most widely stud-
ied marker of inflammation is C-reactive protein (CRP).
CRP may not be merely a marker of inflammation but
may in fact mediate several key processes in the de-
velopment of atherosclerosis including plaque initiation,
formation, and rupture. In longitudinal analysis, CRP
measured at baseline in the Modification of Diet in Renal
Disease (MDRD) Study was an independent predictor of
all-cause and cardiovascular disease mortality [27]. In the
Nurses Health Study, higher levels of CRP, interleukin-
6 (IL-6), and tumor necrosis factor (TNF) receptors I
and II were associated with increased odds of coronary
events in women with creatinine clearance <74 mL/min
[28]. Other pro- and anti-inflammatory cytokines, includ-
ing IL-10, and TNF-a may also play a role in the develop-
ment of cardiovascular disease in chronic kidney disease
[29].
Oxidative stress
Oxidative stress has been postulated as a common
pathway via which other cellular processes such as in-
flammation and insulin resistance culminate in the patho-
genesis of atherosclerosis [30]. There are, however, very
limited data examining oxidative stress markers as car-
diovascular disease risk factors in patients with chronic
kidney disease. Post hoc analysis of patients with el-
evated creatinine in the Heart Outcomes and Protec-
tion (HOPE) Study did not find a benefit of Vitamin
E on cardiovascular disease outcomes [31]; however,
the Secondary Prevention with Antioxidants of Cardio-
vascular Disease in End-Stage Renal Disease (SPACE)
trial demonstrated a reduction in cardiovascular disease
events with vitamin E [32]. Similarly, Tepel et al [33] were
able to achieve cardiovascular disease event reduction in
patients with kidney failure by administration of acetyl-
cysteine, a putative antioxidant agent [33].
Metabolic syndrome
There is a close correlation between components of
the metabolic syndrome and kidney disease; and in fact it
has been proposed that albuminuria be considered a com-
ponent of the metabolic syndrome [34]. Metabolic syn-
drome has been linked to increased risk of cardiovascular
disease mortality in the general population [35] but data
are lacking in chronic kidney disease. Hyperinsulinemia
and insulin resistance are also prevalent in kidney dis-
ease and a prospective study of nondiabetic hemodialy-
sis patients demonstrated an association between insulin
resistance and cardiovascular disease mortality [36]. A
novel risk factor that has been the focus of recent inves-
tigation in kidney disease is adiponectin. Adiponectin,
an adipocyte hormone, is inversely related to several
metabolic parameters such as body mass index, glucose,
and insulin and has been postulated to be a biomarker
for the metabolic syndrome. Decreased plasma levels
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of adiponectin were associated with increased risk of
cardiovascular disease mortality in a cohort of chronic
hemodialysis patients [37].
Hyperhomocysteinemia
High homocysteine (tHcy) appears to be associ-
ated with increased cardiovascular disease risk in the
general population [38]. Similarly, elevated levels of
tHcy may be associated with increased morbidity and
mortality from cardiovascular disease in patients with
kidney failure [39]. In contrast, low tHcy levels were asso-
ciated with hospitalization and mortality in other studies
in hemodialysis patients [40]. Data are lacking on the re-
lationship between homocysteine and cardiovascular dis-
ease risk in patients in the earlier stages of chronic kidney
disease, and whether decreasing homocysteine levels can
reduce cardiovascular disease risk in this patient popula-
tion.
Abnormal calcium and phosphate metabolism
As described in a subsequent section, abnormal min-
eral metabolism can promote arterial calcification, and
arterial stiffness, which may lead to LVH and thereby
potentiation of atherogenesis.
Endothelial cell dysfunction and injury
Abnormal endothelium-dependent vasodilation, man-
ifested as impaired brachial artery reactivity, is a pre-
dictor of cardiovascular disease events and mortality in
patients with kidney failure and this association is inde-
pendent of arterial stiffness and LVH [41]. Endothelium-
dependent vasodilation appears to be impaired in
patients with chronic kidney disease [42], although its
association with outcomes has not been studied in this
population.
Endothelial cell apoptosis facilitates atherosclerotic
plaque formation in several different ways, including in-
creased vascular permeability, proliferation of smooth
muscle cells and macrophages, and platelet activation and
aggregation. A prospective study in chronic hemodialysis
patients noted that levels of sFas, a marker of apoptosis,
were independent predictors of future risk of fatal and
nonfatal cardiovascular events [43].
RISK FACTORS FOR ARTERIOSCLEROSIS
Endothelial dysfunction
Impaired endothelium-dependent vasodilation is re-
lated to carotid wall distensibility in patients with kidney
failure, suggesting that endothelial dysfunction may con-
tribute to arterial structural alterations in patients with
kidney disease [44].
Abnormal calcium and phosphate metabolism
A growing body of evidence implicates hyperphos-
phatemia and elevated calcium phosphate product as
contributors to the excess cardiovascular disease risk in
kidney failure [45]. Potential pathways include increased
large vessel calcification with its associated effects on
arterial stiffening, increased pulse pressure, decreased
coronary perfusion, and LVH. There are limited data
evaluating the relationships of serum levels of phospho-
rus and calcium phosphate product with cardiovascular
disease in earlier stages of chronic kidney disease. A re-
cent analysis of a cohort of United States veterans with
chronic kidney disease stage 3 demonstrated that serum
phosphorus levels>3.5 mg/dL were independent predic-
tors of all-cause mortality [46].
CONCLUSION
Patients in all stages of chronic kidney disease are at
high risk of cardiovascular disease. We have briefly pre-
sented available data from studies exploring the mecha-
nisms underlying this excess risk. We acknowledge that
this is not an exhaustive review of all the potential risk
factors involved in the development of cardiovascular dis-
ease in chronic kidney disease. Rather, we have focused
on a few with some degree of evidence available and that
are potentially modifiable. It needs to be emphasized that
causal relationships are yet to be established for many of
the risk factors discussed. The implications of our present
state of knowledge is that a high suspicion for cardio-
vascular disease is warranted and that aggressive treat-
ment of traditional risk factors should be instituted in
the earlier stages of chronic kidney disease. Additional
basic science research, observational studies, and clinical
trials, are, however, urgently needed to understand the
pathophysiology of cardiovascular disease and to evalu-
ate potential interventions to reduce the burden of car-
diovascular disease in chronic kidney disease stages 1 to
4.
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